CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to NVAX

NVX-CoV2705 Vaccine

Phase 3
Novavax, Inc. (NVAX)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Severe Acute Respiratory Syndrome Coronavirus 2 Infection

View Full Landscape
Drug Information

Target Indication

Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Clinical Trial

NCT06409663

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book
Drug Science
Mechanism of action & safety profile
Developer

NVAX

Novavax, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ
Related Pipeline
NVX-CoV2373 (5μg)Phase 3

COVID-19

XBB.1.5 Vaccine (Booster)Phase 3

COVID-19

SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)Phase 3

COVID-19

SARS-CoV-2 rS/Matrix M1-AdjuvantPhase 3

SARS-CoV-2 Infection

NanoFluPhase 3

Influenza, Human

View full pipeline
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.